Based on the outstanding expertise and rich experience, Creative Biolabs has specially developed a system approach of TCR in vitro assay for TCR development. Our featured assay services are listed as follow:
Since TCR ab gene sequences can be isolated from tumor-reactive T cell clones, one possible approach to generate tumor antigen-specific T cells for therapy is to transfer these ab sequences to a polyclonal or nonreactive T cell population to redirect their specificity. In order to obtain high quality TCR-modified T cell prior to scientific studies, TCR in vitro assay related to TCR construction are needed. Creative Biolabs offers a series of assays for TCR validation including transgene expression, cytokines release, TCR/CD3ζ stability assay and so on.
This method is bioluminescent and can be used for the discovery and development of biological therapies such as adoptive immunotherapy. During our method pipeline, the TCR/DC3 effector cells NFAT or IL-2 will be detected by the anti-CD3 antibody-mediated luminescence and the signal is enhanced by an anti-IgG crosslinking antibody.
The release of cytokines by T cells defines a significant part of their functional activity and their ability to produce multiple cytokines, which has been associated with beneficial immune responses. Creative Biolabs commonly provides our clients the measurement methods including enzyme-linked immunospot assay (ELISpot), intracellular cytokine staining assay (ICS), and flow cytometry, but not limited to them. In response to viruses or tumor antigens, those successfully modified T cells can secrete higher levels of cytokines, such as IFN-γ, IL-12 and GM-CSF. Therefore, we will focus on these kinds of cytokines.
Cytotoxicity refers to the ability of certain chemicals or mediator cells to destroy living cells. Therefore, to accurately measure cytotoxicity is proven to be a very valuable index in TCRs in vitro assay that might pose certain health risks in patients. Creative Biolabs has developed various assay methods, available for customers to measure the cytotoxicity of TCR-modified T cells. We always introduce vital dyes, protease biomarkers or by measuring ATP content to our clients. The formazan dyes are chromogenic products formed by the reduction of tetrazolium salts by dehydrogenases and are released at cell death. We also monitor cytotoxicity by the use of the SRB and WST-1 assay which are high through methods.
T cell responsiveness to an epitope is affected both by its affinity for the presenting MHC molecule and the affinity of the MHC-peptide complex for TCR. One limitation of cancer immunotherapy is that natural tumor antigens elicit relatively weak T cells responses, in part because high-affinity T cells are rendered tolerant to these antigens. Scientists have reported that amino acid substitutions in a natural MHC class I-restricted tumor antigen that increase the stability of the MHC-peptide-TCR complex are significantly more potent than tumor vaccines. The improved immunity results from enhanced in vivo expansion of T cells specific for the natural tumor epitope.
For more comprehensive study and assessment of T cell receptor, we also have TCR Analysis service for our clients to help them gain more insight information about the characteristics of TCR molecular complex they are interested in.
Creative Biolabs has the capability to enable you to free up your time for core work and project. Our service can be designed to meet your special needs if you have any requirements. If you are interested in our service, please contact us by E-mail and our team will get back to you as soon as possible.
For any technical issues or products/services related questions, please leave your contacts as below, and our team will contact you at earliest convenience to let you know how we can be involved in your projects.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
End-to-end CAR Hybrid TCR (CHyT)-T Cell Therapy Development Services: A novel solution to engineer T cell to be a promising cellular therapy with the complete TCR without HLA dependence.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE